<SEC-DOCUMENT>0001144204-13-029144.txt : 20130515
<SEC-HEADER>0001144204-13-029144.hdr.sgml : 20130515
<ACCEPTANCE-DATETIME>20130515114939
ACCESSION NUMBER:		0001144204-13-029144
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130515
DATE AS OF CHANGE:		20130515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		13844780

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v345218_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B> SECURITIES
AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">Nevada</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">1-12584</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(Commission File No.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">155 Gibbs Street, Ste. 412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 - Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 15, 2013, Synthetic Biologics, Inc., a Nevada corporation,
(the &ldquo;Registrant&quot;) issued the attached press release that included financial information for the three months year ended
March 31, 2013. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in
the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant&rsquo;s
registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: black">(d)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="color: black">Exhibits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="color: black">Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated May 15, 2013.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="color: black">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD><FONT STYLE="color: black">Date: May 15, 2013</FONT></TD>
    <TD><FONT STYLE="color: black">By: <U>/s/ C. Evan Ballantyne</U></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Title: Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="color: black"><U>Exhibit No .</U></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="color: black"><U>Exhibits.</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="color: black">99.1</FONT></TD>
    <TD><FONT STYLE="color: black">Press Release issued by Synthetic Biologics, Inc. dated May 15, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v345218_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports First Quarter
2013 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, May 15, 2013 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious
diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Operational Highlights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Emphasis on C. difficile (C. diff)
Infection Prevention (SYN-004)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the U.S. each year, 24 million patients
are administered IV antibiotics<SUP>[1]</SUP> which may be excreted into the gastrointestinal (GI) tract where they can upset the
natural balance of the microbiome allowing for the overgrowth of <I>C. difficile</I> which causes diarrhea, colitis and may result
in death.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SYN-004 is being developed as an oral
enzyme product to be co-administered with IV beta-lactam antibiotics. SYN-004 is expected to:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Remain in the GI tract to degrade certain beta-lactam antibiotics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Protect the healthy microflora from the overgrowth of <I>C. diff</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In 2012, over 13 million patients were
treated with IV beta-lactam antibiotics that may be covered by SYN-004.<SUP>[1]</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase I and II studies of over 200 subjects
treated with 1st generation candidate demonstrated safety, tolerability, and preservation of the normal GI microflora when co-administered
with certain penicillins<FONT STYLE="color: black">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Infectious Disease Specialist Joins
Scientific Advisory Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brad
Spellberg, M.D., is an Associate Professor of Medicine, David Geffen School of Medicine in the Division of General Internal Medicine
at Harbor-UCLA Medical Center, and Associate Program Director for Internal Medicine Residency Training Program, Harbor-UCLA Medical
Center and LA BioMed.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
Spellberg has worked closely with the Infectious Diseases Society of America (IDSA) to focus attention on the rising public health
crisis caused by increasing antibiotic resistance and decreasing new antibiotic development.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trimesta<SUP>TM</SUP> for Relapsing-Remitting
Multiple Sclerosis (MS)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continuing
the 164-patient, randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial evaluating the efficacy and
safety of oral estriol (Trimesta&trade;) for the treatment of relapsing-remitting MS in women.
The primary endpoint is relapse rate at two years.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Through
our wholly owned subsidiary, we hold the exclusive worldwide license to U.S. Patent 8,372,826 and 6,936,599 and pending patents
for multiple sclerosis and other autoimmune diseases covering the uses of its drug candidate, Trimesta&trade;.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">During the first quarter of 2013, U.S. Patent No. 8,372,826 was issued to the Regents of the University
of California which includes claims to the use of our drug candidate, Trimesta&trade; (oral estriol), in combination with glatiramer
acetate injection (Copaxone&reg;).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Copaxone&reg; is the number one selling drug for MS with approximately $4 billion in annual sales.
Currently marketed exclusively by Teva Pharmaceutical Industries Ltd., Copaxone&reg; is expected to face generic competition as
certain patent terms begin to expire in 2014.<SUP>[2]</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Upcoming Milestones</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>C. difficile</I> program:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of cGMP manufacturing expected during 3<SUP>rd</SUP> quarter of 2013</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Initiation of clinical trials expected during 2<SUP>nd</SUP> half of 2014</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Relapsing-remitting
MS clinical trial:</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Final patient&rsquo;s final visit expected in January 2014</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Top-line results expected in the first half of 2014</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;As we begin 2013, we are focused
on building our infectious disease platform. We are especially excited about SYN-004, a 2<SUP>nd</SUP> generation preventative
treatment for <I>C. difficile</I>, to be co-administered with IV beta-lactam antibiotics. While Phase I and II studies of a 1<SUP>st</SUP>
generation candidate demonstrated safety, tolerability and preservation of the normal GI microflora when co-administered with certain
penicillins, we anticipate that SYN-004 should have a broader spectrum of activity including, penicillins as well as most cephalosporins.
There is great potential for SYN-004 to protect the healthy microflora in the GI tract from the overgrowth of <I>C. diff</I>,&rdquo;
said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;As a novel prevention for <I>C.
diff</I>, SYN-004 is a break-through candidate for Synthetic Biologics. With over 13 million patients treated with certain IV beta-lactam
antibiotics in 2012, these antibiotics have become a mainstay in hospital infection management. We are working hard to accelerate
the development of this program in order to provide a prophylactic treatment intended to prevent <I>C. diff</I> infections,&rdquo;
concluded Mr. Riley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Three Months Ended March 31, 2013 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1.1 million for the three months ended March 31, 2013, compared to $1.5 million for the same period in 2012. The decrease of 24%
is primarily the result of lower consultant and legal fees, and non-cash stock based compensation. Charges related to stock-based
compensation were $353,000 for the three months ended March 31, 2013, compared to $499,000 for the same period in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses were
$1.1 million for the three months ended March 31, 2013, compared to $386,000 for the same period in 2012. The increase of 190%
is primarily the result of additional employee costs and increased program costs associated with our infectious disease programs.
Charges related to stock-based compensation were $103,000 for the three months ended March 31, 2013, compared to $9,000 for the
same period in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $12,000 for the three
months ended March 31, 2013, compared to $5,000 for the same period in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash as of March 31, 2013 was $8.5 million
compared to $9.9 million as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a<FONT STYLE="color: black"> biotechnology company focused on the development of biologics for the prevention and treatment
of serious infectious diseases. The Company is developing an oral enzyme for the prevention of<I> C. difficile</I> infections,
and a series of monoclonal antibody therapies for the treatment of Pertussis and <I>Acinetobacter</I> infections. In addition,
the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction
in multiple sclerosis.</FONT> For more information, please visit Synthetic Biologics' website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copaxone&reg; is a registered trademark
of Teva Pharmaceutical Industries Ltd<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding our continued focus of our
efforts in the field of synthetic biology and advancing our clinical programs, the opportunities in the infectious disease market,
the anticipated timing and results of our development efforts and the expected size of the future market for sales of therapies
for CDI , Pertussis and Acinetobacter. The forward-looking statements are subject to risks and uncertainties that could cause actual
results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in Synthetic Biologics&rsquo; forward-looking statements include, among
others, a failure to receive the necessary regulatory approvals for commercialization of our therapeutics, a failure of our clinical
trials to be commenced or completed on time or to achieve desired results, a failure of our clinical trials to receive anticipated
funding, a failure of our monoclonal antibodies for the treatment of infectious diseases to be successfully developed or commercialized,
our inability to maintain our licensing agreements, including our agreement with Intrexon, or a failure by us or our strategic
partners to successfully commercialize products and other factors described in Synthetic Biologics&rsquo; report on Form 10-K for
the year ended December 31, 2012 and any other filings with the SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this
release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>-- Financial Tables to Follow--</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(in thousands, except share and per share amounts)</I></B> <B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(Unaudited)</I></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Condensed Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2013</TD><TD STYLE="padding: 0 0 1pt; font: bold 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2012</TD><TD STYLE="padding: 0 0 1pt; font: bold 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Assets</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Cash</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">8,520</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">9,954</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2,234</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2,509</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Note receivable, current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">215</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">223</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Long-term note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 0.125in; text-align: left; text-indent: 0">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">15</TD><TD STYLE="padding: 0 0 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">37</TD><TD STYLE="padding: 0 0 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-align: left; text-indent: 0">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">11,684</TD><TD STYLE="padding: 0 0 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">13,423</TD><TD STYLE="padding: 0 0 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0.125in; text-indent: 0">Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">196</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">395</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 0.125in; text-align: left; text-indent: 0">Stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">11,488</TD><TD STYLE="padding: 0 0 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">13,028</TD><TD STYLE="padding: 0 0 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-align: left; text-indent: 0">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">11,684</TD><TD STYLE="padding: 0 0 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">13,423</TD><TD STYLE="padding: 0 0 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,122</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,468</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,118</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">386</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating costs and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,240</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,854</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,240</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,854</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total other income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from Continuing Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,849</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income from Discontinued Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">649</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,228</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,200</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Income (Loss) Per Share - Basic and Dilutive</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Continuing operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Discontinued operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net Income (Loss) Per Share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,601,396</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,003,164</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, Ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><SUP>[1]</SUP>
This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information
service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution
and republication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><SUP>[2]</SUP>
Teva Pharmaceutical Industries Ltd. Form 20-F filed with the SEC for the year ended December 31, 2012.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!8`<(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBHY)!
M'MRKMO;:"HRJG!(+MT13C:&/&X@9&:-P)*@RFYU)/)!.`W7((YQV[FO-?'?Q
MD^'GPW*Q>*]?@L[YXUEBTFUCEU'5ID9I45DL+))IE0M$RB241QY_BP"1\O\`
MB']N/PE:R2CP_P"!?$.L<L$EU74M-\/PW`4`AK?[-!KUW(.P$ELK`@@BA0G.
M=.G&,G[23BTE=M)<WRVWT3VN95:D(0]HY)<EFI.[4;M*[23TUZK3R/N,S1%&
MV-&P4/N);(4@$_O,'*\\X.,=.^::)4V##1XRN-IPK$AB`K_=8L`#A26'7''/
MYL_'']N'QG\-=$\,R^&?A%=>*-9UV.RU6]O]/O\`6==\":;HMUAH[-O%MAH%
MN-0\4-"'673[6SDM]/QOO;J,*B/Y/HO_``51AM[AG\8_`?Q#I,<@*0W6B>,=
M.U6>XB4ABJ+K7ASPI&A'+>4FHW<2LH0N2=Z_C'$/CSX7\*Y[6R#/\]>5XVBT
MIPKX?&PPC3ERMU*BPOL^;FBU)QDXN-M6^9+]2R7P8\1N(,HHY_DN11S/`8ER
M=.M0Q>6RQ*M&#]RC+&PK*+NG!.FY7YGRVY6_V(@^ZW&!NXXVYX`Z>F`,5-7Y
M]^"?^"D_[,WB4"+5M9\0>![@HDLD?BK0KA(81(QB`FO])DU:R)#HP:191`%`
M)DSNK[+\&?$KP/\`$33O[8\">*-#\7Z4I9);_P`.:I9ZQ;V\H",(+EK&68VU
MPZ,76"X$4Q5&)C'RY^UX:\0N".+E&/#?$V2YI4:O'#83&TOK%M=88:HZ5>:L
MKMQI-7N?+YWP9Q9PRG_;_#V=97!5'1>(QV`Q%/#RJ:>ZL4H/#2>JMRU6DFCN
M:*J17D4H!`8$KN`QNQP,JSINC5P3@H7W#KC'-3^:I/`...>G7../\]:^QE)1
MOS-+E5Y=;+;6U^KMZGS/-&_+=-Z;-/=I;K3JB2BHQ)DGY2,9[]<#/%/!R`?6
MA--*2U3V?0&TI<K:YK<UM]+VOIZBT444QA115.2]CC+JR2#9(8MQ"JK,(A,S
M*SL%\M(V5GD)V)B0,08I`H!8,T8."P'WN2#M^5@IRV-HPQ`Y/)SCH:&EC0D,
MZJ0,G<<8'`W'/1<G&X_+GC.0:_!']L7_`(.#OV,OV8O$.K^`_AOI_B?]J+XB
M>'Y[BRU>V^&-_I>G_#C1=7MW"W&G:K\3M0:ZT^XNXV9A?-X/T3QDMBYC@NU@
M:=&'Y9W/_!U9X];5[6XLOV%O!5CHUO#()M(N?VF=?N=4ED+EDE35[;X$:1I]
ME`ZY#B?PQ>F)SA;B?H7RR[/^OZ_JS`_LZ,L0&XR*%QD.2`A&`<ASA2,$<@G]
M#2^9'M#%U52<`L=N3_P+'7MZU_,A^SM_P<Y?LL_$/5;31OVA/@U\1?V<)+^Y
MC23Q5I>L6?QG^'6G#S(49]8UC2/#_@[QC:6:/,[7.H)\.[FSLX1'<7-^B-(E
MM^RW[2_[:7A7X!_LJZU^U]X+\':Y^TC\+="TFP\5WUU\&=>\+:A--\/;O>]_
MX[TF_O\`5+;2=7\/>&HT>Z\0RVMY]KTW3H;V_GMA:Z;J#VHTUNK`?;9(4%F(
M``R22``!U))X`'J::LB/C8P<%=P9?F0C.,AQE>_3.3UQ@5_+4/\`@Z<_9E`+
MG]E;]HI44NK!=6^%@F#P[3<1+&_BZ,[X4=&WN\=NP=2)P@=T_I#^"GQ@\"_'
MSX6^`/C)\,M737_`7Q*\):1XQ\,:O$NQ9--UB'S5LKA!_J=4TVX2XL-8L7Q<
MZ;J-M/9W2I,A4(#U6FLZK][(YQ]UCS^`-0W%REO]Y78E2PVCCAD3!8D*HRX+
M,Q"I&LDKE8XW8?B#^WK_`,%S_P!FW]A#XZR?`'6?AM\2/B_XZT[PQHWB/QE-
M\.KKP;96'@FY\1/=2Z-X:UBZ\2:SI4TWB"[TNWAUF2VLDN8;+3[^Q^VW%O<S
MB``'[BDA02<X'7`)/Y`$G\!33(@P<MRNX?(YXSCH%SGGIU[XQ7X-_L:_\%UO
MAS^V]\4M7^&/PM_9:^.NEKX5\!>+_B1XX\9:WJWPY?PWX,\,>%-,N[J*75Y-
M+U_4+HWGB'5X]/\`#>CV-O;2S2:AJL4MP(+2TOIK?Y$MO^#I_P#9DN(([FW_
M`&4_VAXA-!#=C[1K?PIMPB3"1E$[Q^+9DA(1&9R"8P^%,G(8@']4(((!&<'D
M9!!_(@$?B*6OCO\`8C_;1^$W[='[/WAW]H'X26^KZ=I&LZQK'AOQ%X1UU-._
MX2CP+XTT!K==8\)>*%TFZO=.35[:SN=-U2%[>^NH;[2]4TR[MIY8KN$'[!C<
M21I(O1T5Q]&`(R..1GD<'/%``9$'4\Y(`P23@X.`!D@=R!@#DG%*SJH).<*<
M'"LQ'?HH)/'H*_%'_@H?_P`%J?@[_P`$Z_COX>^`GC[X*_%KXBZ_XA^$OAGX
MO1:]X&U+P79Z+;:1XH\9?$7P7:Z/+'XCU_3KY]1MKWX;:O>W`6T:S^R7^EB.
MZEG:\2UX#X1?\%[/@;\7?V;/VK/VFM*^`7QDT;PW^R5:?">Y\3^%]2U'X?2:
M[XK7XN^+G\':(/#4MGK\VG02:9>(]WK#:K>6(6SVBQ-Y.QA0`_>X,&Y!!QU]
M02`<$=0<$'!P<$<4M?RS_P#$4U^S."5'[*O[0_RG!QK'PI'.`3_S-N3UX)Y(
MZXZ!?^(IK]FC_HU7]H?_`,'/PI_^:Z@#^I>D+!1DGU]R<`DX`Y)P"<`$U_+3
M_P`137[-'_1JO[0__@Y^%/\`\UU(?^#IC]F=L#_AE;]H<-GY?^)U\*A\V&89
M8>+"5'R<E<D''!%`']2P=2`P)P1D9#*3WX!`/0=,9I`ZMTW?BCC^:BOPJ^/O
M_!=#X)?`/X`?LC_M#Z_\!_B]X@T']K[PCXD\8>$]!T74/`$>O>#;3PS=Z-9W
MEMXCDU'7;73YKVY.MVC6[Z3>WT31PW"S2Q%(1-+^P=_P7.^"W[>_[0ND?LY^
M"?@1\7/`7B#6/"OBOQ=!XB\::EX#N]"M[+PE9Z=>7MH\6A:YJ6H"ZN4U.%+,
M1V;0[DF\Z>%1&7`/W3I"<#)_D3_*EKQ#]I7XUZ+^S;\`?C#^T%XCT+5/$^@?
M!?X=>+/B3K/A[0WL(]:UG3/".CW6LWNGZ1)JDUMIZ:E<V]I)%9_;;JUM6G9%
MGN8(BTB@'M@D0DC)&.N591UQU8`=>G//:D,L8.TNJDG`#';D^@)P&/L,FOY:
M6_X.E_V9G*F7]E7]H9]T@C"MK/PJD0J'96WAO%8(6,#?$H#;G)!,8^8_J'^W
MO_P51^&G_!/_`.&7P$^)?CKX6?$?X@:?\?WN8]"TKP5?^%+6]\/K:^'--\3N
MVL2:_JNF6TCM::I%;`6$EPK744N2D)20@'ZKT5_+1_Q%-_LSG_FU7]H?_P`'
M/PI_^:VC_B*:_9H_Z-5_:'_\'/PI_P#FNIM-*[5E_P`-_G_5F!_4O4?FH"PR
M<H2&&Q\_*J.<?+\P"NIRN02=H.X$#^6S_B*:_9H_Z-5_:'_\'/PI_P#FNKW+
MX9_\'$'P`^)OPB_:8^,&G?LZ?&_2]+_9F\(_#'QAXBTB_P!3^'$FJ>*;?XI_
M%CP]\)=,L=#GM_$LUK!-IFI^(K/5-1.HS6D)TJWN8[1KB\$,$B`_HEHK^6C_
M`(BF_P!F<_\`-JO[0_\`X.?A3_\`-;1_Q%-?LT?]&J_M#_\`@Y^%/_S74TF]
ME?I^7^:`_J7HK^6C_B*:_9H_Z-5_:'_\'/PI_P#FNI#_`,'37[-&#_QBK^T/
MT/\`S&OA4/U_X2TX^N#]#2`_J5$B,<`\]L@@'C/RD@!N.>">*5G1!EW5`3@%
MF"@GTR2.?:OQ4_:`_P""TOP>_9Z_9/\`V3_VM]=^"?Q5\1>%OVL[*XO/#'A/
M1-0\#P>)_"B6VB#62GB:>_UFUTFZ=X66)?[+O[Q5FRQ.Q0Q\N_8U_P""_OP+
M_;._:=^$_P"R_P"$/V?OC1X*\3?%JZ\:6>D^)_%.J?#Z?P[I3^"_AKXT^)U\
MVJPZ+XBO]3=+O2?`^HZ?9?9+*X/]J7EBLZPV;7-U;@'[^@@YQV.#P1SP>,CD
M<]1D>_!HR.3GIG/X=:KHXC0`AR,D`@%BQ!(;:HW$;54L57L#M!.0/RO_`&V/
M^"QW[%?[#&HZEX*\=^+=9^(GQCL;>*[NO@S\)K&R\2^-=+CN\&VF\4W%[J.E
M>&O"%O)DDG7]:M;I0A"V4CF.-P#]5//ARH,B@OC9N.T/E6?"$X#G8CN0I)"*
MSD!030)X2`PEC*G(#!U*D@X(#9VD@]0#D>E?QM^+/^#J7Q1)?&/P%^P_H=II
MEO<H;>_\8?M$:E<ZA?V0+ES/H/ASX/6%CI-XZN0"OB'7K='V2X<Q@/[;\$_^
M#H_X4>(=;L]-^/G[*?CSX7:==W$5K=>*OAE\1[#XRV=C'(9,ZAJ'A[5O!GPS
MUY;:-5#26^D+XDOE0/Y4,^P;P#^KM6##*G(!QGM^![CW&1[TM>!_L^_M+_`W
M]J#X:Z7\6_@#\0]!^)?@'6)GMH]6\/SLTVF:G!;Q276@ZYI-RL&J:!KUMOB\
M[1-4L[2^7[1!(D+0W$,LGO$4@ECCE4$+(BN`2"<,,C.TD9P><$X/%`$E%%%`
M$<K%(W=<9520"I;)'\(4,I);[J@$<D=>A^(/VG?VC+_P?<'P!X#O(8/$4D$S
MZ_KL:I--X?C:.+R;&T5V:*/5;B.<S&XE25(889`D2RLKI]MW=S'9VMQ=S9$-
MK!+<2D#)$<*-(Y`[X52?PK\#9K[4/&GB.34;V3S=4\4:O)=W;1$L4GU6X@9H
MY6.3(T,,0122`%+8`SBM:5-S;::2CKK?7K96$U=-=SL?`_P^UOXA:F9//O52
M]NXU%S<&?4-5UF_N-N5M99W>5IR3OO\`5;O[1#IUJUONC\I45?T3\`_LO>%/
M#D<5QJT"SW899FM8@AD>0+AH[S4ITEFGPP^66T%G&P^<(N0!J_L\>$;+3;&_
MU"&-%&FO'H&FED!>+[/&EU?W$3$EE:Z-V(9N3YBVZJ3A0!]-""%AG;D$GCH.
M"0,8Z`#@8[?4TJCDFXQJ3I-:.=.W-OJDWM]SOM8S]DG\6J_D^Q/;W9[/EZZ;
M-)V>QP^G^!O"FD1RPZ?H-I;)<JXN<*\D=T9#NEDN(7=HII9V"O/*T?FS.`TC
M-BN8_P"%)?"S?J$W_"%:$)-4F\Z\S9[5D?9SL0'9#&WWC%$$B+_,5R`1[#Y$
M7]P?K_C3A&BC`7`^I_J:^<S7A;AW/9\^=9'D^:.,.2+QV68;$U7JY<TJU1<Z
MNV[PB[/XKINQWX/,\TR^W]GXW'9<FH\RP.98JA'FBTXM0@E"ZM=.RL]EW^0_
M&'[&OP`\5QNMUX,M]*ED)9+S2IY$:&8@J"JW"W5LJC*G8(0O?US\M?$;_@GY
MJ6D^`K[2?@+\0]<\&^)#X]TOQW_:]GJ5SH6JNFA^'-8T33](AUBQD*>4M]JR
M7MPF_3871"#$,%F_5\PQ%M^P;MI3/7Y3VP>.Y[4S[);GK$I.&`;D,H<*&$;`
MAHPVQ"PC*@LBL<LH-?/\/^%OA_PSQ3@>-,GX3R3+^(L!%QPV+P^!@J=&,E:4
M(X?G5&::ZS@VFVTN_P!;3\2>.?J$,KQ?$>:YIE=/$1K3RK-\=5S+`8M0Y9+V
MU.NN:D^9:QI.S26NNGX5:'^V3^V%^RQK$/AG]I?P'=_%SPK`K-'XKTVUCT+Q
MW::?$P,^HNL:?V+XGMX(]SM$BL%"L9O$L$:NP_4SX%?M.?!W]HW1#K?PN\76
M6LM:00RZQH%R#I_BC0GG2-HTU/097DNX(R#(1>1&>QGV*MI<7,<GG)[#XG\*
M>'/%VD3:'XET:RUW2;@JS66HPK<1),K86X@WD-:W,(9C%=6[1W$!)DA;?C/X
MX?M&_P#!/77O!6MK\9_V:==UKPIXJT![C4XUT26]@U>TV,+E\/IVV[U[37\K
M9>(]K=:A.`HGLM5C$D=?M-/^P\Y;INC1R/&NR7L7.6"K325E4O>I!2UM:#UL
MKOITTI<*<7)T,1AJ/#&;1LJ;PSE/*ZU3W4E-2DJE)RO)+EA9R:YY3=K?MC!<
M>8IX&`VT')8,`,A@02F&!#`*\F`P#L'#*MN,[D!QCKQ^)%?D)^R-_P`%%E\6
M:U9?!/\`:2@L?`_Q7\^VTS0O%,#06'A3QU=70\FT'DDR6>AZ[>3JPM[:.ZFT
M?6+P3Q:5+%+#+8P_KG#(XC7.6P"2<YZ,0<DA2".`1C`.0,XR?!S/`8G*<2J&
M*I.$91YJ55+]U43:M*#T;33NKI.V^NB^1S?)<?D.+EAL;1DHM7H5TW*G5IW2
M4Z<K)RB[IW:3CM*,7H6Z*8IR!@D\XY[\$^_MW[4^N/<\W^EYA7\^?_!Q/^U=
MXR_9T_8YT'X=_#K5[KP[XF_:9\:W_P`-]6UW1[R;3M7T_P"'6C:+/XB\>)I]
M_;?O[";7H7T[PM=W4+"?R==*(0LK8_H,K^>7_@XJ_90\??M$?LB>'?B9\-=*
MO_$7B/\`9C\<:IX\\1>'=.M+F\U#5/AGXA\//I/C6\L+2U8S2KX>2RT#6;^X
MMHYY;;1]-U^[,"/8N[`'\9O[#G[(GBG]M_\`::^&W[,_@_Q%I'@:[\4QZUJV
ML^+=4L;C4+;PCX)\*:7+J6OZW%H"3Z-<:Q<V4"#3-'T1+[3+2]U*:%;Z^L;(
M7%]:?UVZ=_P;$_L40^%(-)U'XO\`[3.H>)&BB-QXHT_Q/X`TV-KMHGC:XM?"
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MGPOXET:+4]3AM_$WABUUC2=1@UK1[PZ1J6G:A;:A8QZ3?3:AI6G_`*F?\&U/
M[4.L-\4?BE^PQXSNXO%7PC^*'@CQ3\2/"?A;4GM]2TG0]?T-M/L/'^C6NB7;
MO9P^'?B%X<U=Y_$VC6]I>:=J>JZ2FKXAU#4-=N=0_8C0?^"LG_!&W]N9?"_A
M?XV7?PYBU*RNY;CPSX;_`&POA%I=OI6@:SJ4=E;WJ6OB/Q1INM^`-/N9E2RC
MO=1'BJWA*P6S2W\BF-(_U:^%G[*/[)'P[U?1_B5\'OV>O@'X*\1RZ1_Q)?'7
MPY^&_@;1-5DT;5K5&WZ5XF\/:5;W4NFZC9R(\4UK>&"ZM9$=&:-Q1)MI733U
MWZ[:[`?YZ?\`P5E_8#U']@']J?6/`F@V-Z_P0^)$-_X^^`VM31/-"/#1U4Q:
MCX#GOWG42Z]X"U&Y@T:\29UN/^$>_L#Q%<1N-9@2']7O^#</_@H,_P`-_B!J
M?["7Q(UJ#_A$/BOK6N>,/@-?:K<I:6VA?$N6RAO/$OPZM96C8);>.(M.OO$.
MGK`392^)+2_&GV7]J:[<)??T:_\`!4C]A/0_^"@/[*GB[X50#3+#XJ^&?M/C
M?X(^*+Z-/LNF_$?2[.2+2]%U:5EBF'AGQU;&3PCXGN(IB=/BN+?6([6[N-%M
MX&_S5I(/&?PU\:-;3G7O!'Q&^''C"W*QS)-I_B+P=XX\#Z]:M;J5MI4?3_$G
MA[Q+I:):VEE+#<+J5KIM_IDC:K>0P10!_IW_`/!03]M#PI^PI^S!\0?V@/%-
MO::QKFFVDOAOX7>"I+A[9O'WQ,URWGB\)>&`X24I97-S!-J_B"]0JVD>'M+U
M)U%Q(JBY_P`QGQGXU\:_%CQ_XI^(/C/5;WQE\0OB3XHN_$?B#4R9+K4?$GB[
MQ+J\EW-<VUK^^`CU'6Y+>#3XK87(BL;*QTU;(V]OA_O;_@HG_P`%+/B]_P`%
M$]5^"MW\0=/M_#&A_"'X;Z=HUOX8TC5%ETOQ'\3=1BM4^(_Q9G:.WTZWM9?$
M4XL+?3=*L;>]L]'TS2+5-/OO/O-2W_I=_P`&\'_!/-/CI\7[G]L[XEZ8EQ\*
M_P!GWQ4VF?"C2[VSEAMO'7QLL[:+46UNV1B$M]'^%5O<Q75S,+>5-5\2ZOHZ
MQ<^'-1MI0#]Z/^"9/_!/ZU_8)_81\;Z7XK@AE^/WQA\`^)_&_P`;-0\H&ZT.
M];P->OX/^%UK<;G:VTGX;:'=3PW%@6>&_P#%VO>)_$R"%=6@M8/\[;25)TG3
M6#'S#IFG;'94<)*$DDCE,;JT4ICDC1Q%-&\+E<2(ZG%?ZXWQ8MX4^%WQ.F6-
M1*?A]XSRXSN.?#FIY)YZMD!VZN$C#$B./;_D;:>[1:%93!"_D:/93,B\O)$M
MM<K+%$@Y$I5_-2YY6S,/GR)(@*D`_9+_`((S?\%"/^&%/VGK/2O'%Y*/V=OC
M[?Z)X&^+UK)/,UGX1O9+B+2O"7Q:$#I<K=+X+^WC3_%4[*MW%X#EU"8?VA/9
MVENG^C?:7=O+8VEQ;RPW,-Q;PSPRVTR7,,\4T:R)/#<Q@)<0S(PECN4`2X5U
ME0!9!7^7K^WA^Q1XH_8X\8_#&SNI-3U?X6?'SX+?#GXO_##QE>6ZQ6NM0>)_
M"6FS^*O"FH7"2O"FN>"?%NL36]_8D/YOAC5/"VL;8)M45(_ZKO\`@WE_X*,7
M7QT^$DO[&GQ6U7S?B]\"=&-]\,]7N;L/=^/O@=%/;VMMIX2[8W+^(/A9>7T&
M@W,;22?VCX/N/#&J6^9(-1CB`/R4_P"#GB,)_P`%%_AH023_`,,4_";.<=OC
MM^U#CIT_U[9^B],'-C_@BS^R_K7[9_['_P#P5#_9E\/>+M,\!ZO\4K7]DVTM
M/%NLZ/>Z_INC'PSX\\6>-9WNM)T^\T^[NUO+7PW<:?$8[V`6]Q=03R>9&CQ-
M#_P<\'/_``46^&&>_P"Q3\*B>?3XZ_M-8YZX!Z5]H_\`!JE&DA_;?#J&P_[/
MA'8@B+XL.,$8(^9$;@C)5<]!0!Y3'_P:P?&^0%Q^V/\`"DEFR=OP=\9LH)5<
M;'/C=-ZE<-D*-I8Q$LT9=_QF_P""CW_!/GQ5_P`$XOC%X,^#OBWXH:#\6-1\
M9?#&S^)T6M>&/"FH^%;33+"Y\6>*?"9TJ:SU?7-8FN[M;GPVURMS'-!&899,
MP`H,?Z>"(L:[4&U020HS@9.<*.BCT484=@*_A9_X.B%7_AN'X%DJI+?LJ:$K
M;E#94_%OXMQ8Y!Q^[N)EXQQ(3U"E0#\O?^";W_!/#Q9_P4@^*OCWX5>#_BEX
M<^%5_P"`_`</CNYUKQ-X9U/Q1:ZI;SZSI.D_V59Z=I6K:/<PS6YU>*274I;I
M[:5X)HX[9&*JO[)-_P`&L'QPC*,?VQ/A0P+QH`WPC\80<LX0L';QI,&V1/,X
MBVJ975%\V)=S5PG_``:XDM^V!^T.S<D?LY60![@/\2]'=@/12_S;1\H/0```
M?W(LJMMR,[3N7KP<$9X]B?S]:`/X3/\`@N9^S]JW[*7[+7_!*W]G77?$^G>-
M-7^$7P^^-7A6_P#%.DZ5>:)INN36-W\.[Y;VSTJ_NKV\LH9!,D9AGNYY!M=@
MXW*%\*_X-S^/^"GO@D>GP9^-7_IC\)U^CO\`P=6@"_\`V)P!C_1?CUGW/E?#
M,9/J<`#)YP`.U?@=_P`$T/VS]#_8'_:LTG]HO7_`6L?$FPT;P'XW\)?\(KH.
MNV.A7]Q=^,-/T:WM+U+_`%*PU&".VM%TJX6]C6)<2/N#+MP0#_3^KX$_X*I_
M\HU_VZO^S6/C5_Z@NLU^'?\`Q%4?"C_HS;XG_P#AT_!O_P`H:^>OVM/^#CGX
M:_M+_LP_M`?L^:=^RM\0O"FH?&CX0>/OAII_B;4?B/X6U"QT+4?&/AR_T+3]
M2O;&UT`37-I;7E[#)/$DD3.BE%D0L&4`_E+ZF+_KX4?]_+V*`_DLS$?[07.1
MD'^NO_@Y$/\`QBC_`,$WSW,NK_3GX3>$NOL._H*_D34JWE%>AGB.=S$L3JEM
MESG`57.6B50%\@Q'&6)/]=?_``<B<?LH?\$WSUQ+JYQZX^$WA(_Y'>@#^<+]
MA[]E'7/VX/VF_AW^S+X8\::3\/-8^(=CXOO;+Q;KVC7GB+2[!/!O@K7?&-X)
MM-TV^TJXN?MJ:!/I]L([R(PO=17$ADC@D63]]O\`B%=^./\`T>-\*O\`PSOC
M+_YN:_%#_@F-^U1X!_8N_;9^$G[2'Q1TCQ3K/@GP!9_$6SUC2?!%IIM_XBDG
M\6?#/Q3X2TTV-EJNIZ)IT\D%YXCL7NDN=4LT33XKF>(S7$<,,O\`5_\`\1/W
M["'_`$2S]J'_`,([X;?_`#TZTG?Y6UVWO_PP'YW_`/$*[\<?^CQOA5_X9WQE
M_P#-S7T=\(/^#=SXM?##X$_MA?!R\_:B^&VLZC^TWX$^"W@_1]<M/AKXHM+/
MP=<_"WX[>&/BU>ZEJ]C+XIN)]5M]:T_PS)H%E:6=S936VJSK-+//"6BA^@O^
M(G[]A#_HEG[4/_A'?#;_`.>G7ZV?L-_ML_"[]O\`^#%W\=?A'HOC7P[X0M?'
MOB#P,UC\0+#2-,\0C5O"UOH&HWDPL]#U77+`:;-'K%N+>0ZDTI>-I'7]X!68
M'\P1_P"#5WXX*/\`D\;X58&!_P`D<\9G';.!XYR<=<<9]0.1^)?_``45_81\
M3_\`!.SX^Z#\`_%GQ'T+XI:IKGPA\)_%Q/$OAWPSJOA;3K:P\6>,?B5X1M='
MDT_5M1U:<WEO+\.+N\DE6]96BOHOW:8`'^H0X!1L^A/XCD'Z@@$>XK^";_@Y
MR`'_``4:^'H"J,_L7_"-R0JABS?&O]IA22P&YAA1A22H.2`"S$U&7+TTO=VM
MKLO+:W_``^!/^":__!-[Q=_P4F\=_%+P)X1^*_AWX3W/PO\`"&@>+[S4O$GA
M'6/%MMK%OKVN76BK96EOI.KZ,UM-:O:--+))<RDK-&1#LR:_7_\`XA7OC@4R
M?VQOA2!@DG_A3GC/`'<X_P"$Y!X].#VR.M9W_!K'_P`G#?M<#`P?@S\,N=J[
ML/X\U\,-^-^TC^'=M!Y`!R:_MG````&`.`!2;NV^[N!_%3_P7/\`@-J?[+O_
M``3I_P""8W[.^L^)M/\`&>K?![6_%7@?4O%.DZ9=Z-IFMW>C^!K>.:_LM+OK
MN^N[.WF:3]W%/>7#X7<9#N`'YA_\$*1G_@K=^QB<@;=9^/)QW8M^R9^T`,#G
ML`2?Z=_W7_X.HV8?!G]CU<G#_&+XAELG.2/AY9D9)R>#SUZ\U^$__!"ID3_@
MK9^QJTCJBIJOQ[<%BHPR_LG?'W+$LPQ&D1E+D`X)CSA<FD!_5;_P77_X*0Z[
M^P_\#/#OPW^$&J6VE_M"_'^/6-+\.:]YL9O/AGX'THH_B7XAV<+VETLGB!7D
M72?!(E53%KC3W]HXO-+CD3^$'X2?"+XK?M+?&+PU\(OAAH&M_$;XN?%#Q+*V
ME::9I+O5-9UV:"YU?5_%NOZW>SN+"TTNP34O$'B_Q#>232:?IFGWVI7LMR;Z
M!8?TL_X+O_%W4/BS_P`%0/V@H7OVN-$^$]AX#^"OA:.*<C['IGACPIIGB'Q+
M:S)"52.X/Q)\4^-;C<09S;M:;G"A(T_7C_@UT^`6ARZ9^TE^TYJ>GVMYXBM=
M9T#X)^$;B:V\^?1-,2Q/C;QA-8RR@FTN-:75?#5HTEN%,MK`EI)(]JWV=FTT
MD^X%3X,_\&N%G-X<M;O]HC]K#6['QC=6"RWWA;X,>`=%&@>&-1E2XE2SD\:>
M-]4U2[\6000);275VO@OP3&]Q++:V0N8(1J,GYR?\%'O^"$WQL_8:^'VL_';
MP3X_T[]H7X!^'8H;CQIJL7A4^$?'?@"QNKR"Q@U+7_"ZZUXCTKQ-X;6[N;6W
MOM=T74[4623/J.I^&XK"R8R?Z$@1%X"@#)..P).3M'1<GD[<<\]:Y?QKX8T7
MQEX2\3>#O$5BNI^'?%WA[7/#7B'37&X:EHFNZ7<Z5J=BVY),?:;.ZDBWLK!0
M<%6!VE`?YDW_``3F_;G\>?L"?M*^$/BKH%_J%Y\._$6L:1X>^./@-[F[.C>.
M/`%S+/%?WIM[D6T$/BCP>+6YU?P=K?ERRI<Z1%`DTNB:C)I(_P!._0M7T[Q!
MHFCZ]H]VFH:1K>EV&KZ5?QDF.]TW4K2*]L;M"V&*7%K/%,I(!*N,@&OP/3_@
MVV_X)G"%[9="^.489!;%!\8M4D5%D2+8'C&F>6Z&.-(TEVJR1`Q1;0"[?N/\
M*_AYH/PC^&?P_P#A9X6EU:;PU\./!OAOP/X?EUW49=7UJ31?"^D6FBZ8VJZI
M.J3:A?FSLH?M5Y*BO<3;Y64%L``[ZBBB@"GJ%JE]8WEC(Q6.]M9[-V`)*I=1
MM`Q`!&2!(2.0,]2!DC\(_"0DT7QIH5EJ"M%<:=XABTV82_*8+BUNCIACD;D*
MRFVA7.<?O!AF4$U^\S9VG:0&QA2>@)X&?QK\E_VN?AU/X)\=R^,;"W*^'_&8
M:^CE0XBM/$EK&!=V<H"J%N;V*/[;IZ1-(KR6\_G/"WEA]J-1PE90=12T<8V4
MWO;E;NM]7=-63[DR4W%^S47/[/-?EWUO9I[7Z[GW#\!]3B.D:YHF5>6SOX-0
M(&#NM;N"&U:/`&0T<MFY;)S\P.!Q7T+&?E"DY(W`8!Q@$[<>VW&*^1_#>B:Y
MX'\3::\6KZ'K>MRZ7:W'B+P]#=QVFOBQNHE6[,&EW`A:Y:*\BNDM2'5RL8WK
M&"N[ZOAD5XHVPZ*Z*1&P*NH*[@A5N=ZKC>IR58,,\9KS8YCA\57K4L)4HUZ^
M'J>QQ>'C7I.KAZK2:YE?X>6ZM;FYFNB9I:-DU)2]U7L[I2TNO1;7[]2[GM13
M0?N]><_ID<X'],?E3JZHN_,FUS1=I)7]UV3M?J[/=:$M6W"BBBJ`JA&&WY2>
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M&!!(4J9%.""AD0`@$AS\J_RS_MI?M$Z'_P`$_P#_`(*.Z+XQ^/7PWU#X@?#R
M?2I_BQ\)OB1\/ETW1_&.A6FIV&O:)>^#_B-X;FTU-)^(6B^$_%D.IS:3X@L+
MW2?%&@Z3J=I<R?VW>R6UE7O8KC+*\%D57#<1PEB(TDEA\7%R=6C-JRA)VDE2
MM>+O%KX4VMG^[>&N6YQXJT,?P)@\JGGW$6$RG&YKDM",U#'8I9=3C4Q&&P]2
MI*,7-8=SG&FN:52G"45"2@T_ZF8IX#+&@DR9&.SY6`?$?F8!*X.$()(.`=R$
MAU*C0K\I?^"0_P"VY?\`[<W[(W@[QUXSN;,?&CX=WT?PP^-T-E`EHM[XWTC1
M=(U*+Q/!8A@]KIOCG1+_`$[Q1`L2&S2^N-4T^&1CI;D_JU7S>$Q5#&X:CB<+
M/VF'JP4J,NK@TFK]+]'V:L]4?DW$W#.<\&<0YUPIQ#A9X#.LAS"OE^8X"I%Q
MJ82O2:_=S;;4U.#C5IU(VA.G.$HZ-!3=PY`#9Y_A8#C'<C'<8]>2,A6PZOX@
MO^#I3X`:K:?M'_L]_M)SZ%!>^"_&GP?7X)2:M]D%R=,\;>!/&GCCQA'9ZEMD
MB>V/B'PS\09KC29(Y+5[JT\%ZW)+>1QZ6`>@\,_<7]K3_@@Q^PC^U+K&J^,]
M+\.^)/V=_B+KD]W>7_B;X-7FFZ+HNJZQ>.9)M1UGX?ZOI&I>$KVYO./M[:/:
M^'KR=(P/MC.K./PR^-W_``:]?M-^%(YKSX$?M"?"CXQ:=;19AT3QOX7UGX/^
M)9RSD/:6Y@U7Q]X9O'2(`_;[C7-!BF<$_8(1\H^)O^"&7[?WPN_X)\_M'^,D
M^+L,^@?!3X[^'-#\+^)_%&D6;74?@[Q5HVJ377AOQ;JFEV6GKJ%]HL$%[>:'
MKT]IY]W:6%W;:O\`9KB'2YH&_O/\'_M=?LL?$;0O^$H\#_M&_!#Q+H4%M#?W
M6I:7\4O!$R6%K/`URO\`:L,FMQ76CM+;*\ACU2"SFC16D=%52U-.SOV`_P`R
MO]IO]C?]I3]CCQ;9>"_VC?A-K_PZOM9DGB\-:M>26>K^$O%JV\Y@E/AKQ7I3
M3Z%J,L`*27.FQWTFI6=H\6H7<$-C<Q3-^MG_``0+_P""B7Q&^`O[2?PZ_9,\
M4^)-3UW]GC]H+Q`O@_PSX6U6^EOM.^%_Q,UX3#PUK_@>*]61M'T[Q=K$=AI7
MB3PM8+#X?N-2\36_B>-9=;?5=GZ5_P#!P5_P4&_9'^)/[,5M^S!\,/B#X,^-
MOQ0\1>/?!GBM+[X?:WIGC+P_\.M(\,WU_-JFKS>+],EO='CU?5--DOO#MM;Z
M1=3WUG%J%W-J&Z!8+6;^<K_@E=\)_$?QH_X*+?L9>&?#5I=3R>'?C_\`#GXS
MZY/:QR3C2_#'P3\3:5\2]7OKZ14#6=A<KX0;1GN)(XXYK[5=/MF6(7J!6Y.6
M]M/Z[@?Z?5TC26TZ)M+O&RH'4R1[R,+YL8*F2+=CS8\CS(]R'@U_$]_P<I?L
M/:%\-?B#X(_;:\"M:Z3:_&C4X_AO\5_"D*+9R3?$;3-*O-0\.?$?2[B.9_M-
M[XD\-6<FB^,;::VM52\\)Z/JD4MY<ZUJ#0_VT5_,[_P=$<_L;_`L>O[2&D_^
MH'XSJ0/XU?V;?@5XG_:A^/WP?_9Y\':E8:)XC^,7CK1O!=EK.HO*-/T.&YCO
M;G7?$DZI^]EBTC1;"]U4VFG-;:MJCA;>SN[748-+NK?_`%%/V?\`X!^`/V:?
M@S\._@;\+=$.F>"?AMX9L?#^C12>5%=7MU`R76HZWJCP#]]K/B'6S<:YK5\%
M6-[NYF\B%(=D2_YS?_!'XY_X*=_L2#T^+EP/_+$\7'^M?Z;E`'GWQ:_Y)5\3
M?^R?>,__`%'-2K_(KM_^1;@_[`5M_P"D=S7^NI\6O^25?$W_`+)]XS_]1S4J
M_P`BRV&?#</MH-N?RL[F@#_2!_:6_84\/?\`!0'_`()=?!WX13/8Z5\2M!_9
M]^%'C3X(^+;J"-W\-?%#3_A=I$6B)=7#2));Z!XE62;PWXA:/+P6FHQZK`DU
MUI,$1_@'^&WQ#^,G['?[0WAKQ_X;AOOA]\;OV?OB-<W<FB:@DMG<:=XE\+WU
MSIVO^"_$=J\<<U]H?B>*TU/P5XFL(@LFK:?KNJF$O+)!#-_J"?LN0//^S!^S
M<H*B,?`+X/HZMN(8-\/?#>]2B[=P:-FVN9`8951E1LMC^7#_`(./?^"=3VTT
M7_!0/X3:/E`FC>#_`-I;0]/M/+MS(R?V/X"^,;%3(]I,;ZZTGP5XMU&)4@`M
M_#>M,1?0:A.:BDW9Z?\`#H#\H?\`@MA^U%X%_;-_:%_9C_:*^'<DD.@>/OV$
MOAA)?^'[J\AOM0\&^,]%_:!_:@TKQCX/U.2,1NFH^'M9BN;`2RP02:QIT>EZ
MLD$=I=6S2?KI_P`&I_WOVX/][]GS_P!$?%JOY`$488Q>5A[FX:5EAVR,T:6H
M9&4LQ_=A8(Y+QEA%PB0W*QM/=W2Q_P!?_P#P:G_>_;@_WOV?/_1'Q:HDK-+R
M_P`P/[`*_A8_X.B/^3X/@3_V:MH7_JW_`(JU_=/7\+'_``=$?\GP?`G_`+-6
MT+_U;_Q5J0-/_@UO_P"3OOVB/^S<[#_U9.CU_<I7\-?_``:W_P#)WW[1'_9N
M=A_ZLG1Z_N4H`_CS_P"#J[_D(?L3?]>OQZ_]%_#.OY[_`/@GQ^Q?J7[?O[2N
MA_LVZ1\3K3X27>L>"_%OB^3QC?\`@>7X@V4<?A*.&\DTQ]#M/&?P^O\`S+BW
MN[6(R0ZV\,8N%?\`>`.@_H0_X.KO^0A^Q-_UZ_'K_P!%_#.OSA_X-S_^4GW@
MK_LC/QJ_],?A.@#]!/\`B%+\;_\`1^/A7_Q%_5__`*(>O"?VH/\`@V]\7_LR
M_LZ?&W]H:[_;/\/>+[3X*_#+QA\2KOPG9_LXZGHMUXEM/"6BW>K76BP:S/\`
MM`7]KIDE];V\L*W5SI.JQJS*/LAR6K^YRO@3_@JG_P`HU_VZO^S6/C5_Z@NL
MT`?Y@1.6B/S<R6>=Q7?Y@O+`3E@D<<:L\XEDVQF5`'`$SMN"_P!=7_!R(,_L
MG_\`!-\>LFKCZ9^$WA(9_#.:_D5[Q_\`7Q%_Z<[2OZZ_^#D/_DU#_@F__P!=
M=7_]5-X2H`_G-_8/_9-OOVY/VI?AS^S!IOCZS^%]W\0X?'%[;^-+[PG)XU@T
M./P7X"UWQ?-%)H$'B+PI/J1U5/#HM(U37]/%J;]+UVN5MGLKC^AG_B%+\;_]
M'Y>%?_$7]7_^B'K\4?\`@D-\?OA1^R]_P4$^!WQP^-WB=?!GPS\)Z;\58]<\
M13:=J6HK:-XC^$_C#PGI0^Q:9:W=]*;C7=1T^T(AMY&C%VDS@1)*\?\`:;_P
M_J_X)9_]'*VW_A"^/_\`YFZIR;5M`/Q@_P"(4OQO_P!'Y>%?_$7]7_\`HAZ_
MH#_X)A_L(:K_`,$[_P!FR\_9\U3XDV7Q=O+OXG>,OB'+XST_P;)X&LV@\3V_
MA_3X=);P_<>)?%-QYUI:Z$K/<_VS<"02*NX"-7D\;_X?U?\`!+/_`*.5MO\`
MPA?'_P#\S=?1'[,?_!3[]BS]L7X@W_PN_9W^+D?C_P`;:9X9O?%]YI$7ASQ'
MI'D^'M.U.VTB\OS<ZUIEA;[8;Z[MXO*$GFMYBE4(J0/OU_N-_NM_(U_!/_P<
MY_\`*1OX>?\`9EOPB_\`5V?M,U_>PW*L/]D_RK^"?_@YRY_X*,?#I^S?L6_"
M/`[\?&O]I@G/_?0_6@#W+_@UC_Y.(_:W_P"R,_##_P!3W7Z_MHK^)C_@UC!'
M[0W[7#=O^%-?#$8[Y'CS7R?;H:_MF!R`?4`_G0!_*'_P=2?\D:_8[_[+#\1/
M_5=V=?A)_P`$+B!_P5M_8Q_=F1FUGX]K'W"/_P`,D?M","P[AT1X^W+`9Y%?
MNY_P=1#=\&?V/6'1?C#\0R??_BWMFO'XFOPI_P""%&/^'MO[&P.?GU/X]1`#
M'5_V4/CV^[)Z%1"5!P?OD<#.0#AO^"QWA34/!O\`P5!_;+TC4B[W&H?$_2O%
MMN[`!3IOCWP#X.\9Z44D#-$T$5AKUM"\P?9#(C17)@G5X4_H]_X-<_B!I>H?
MLQ?M%_#(201ZSX/^.6G^-YXVRMW)I/COP5H^FV4IMVD24VR77@?4(UN0@A=[
MI4&69`W@?_!S+^Q)K$]WX!_;R\%:2]YHND:#H/PA^.QM4+?V59V_B.0?#7QQ
MJ\21MG2;G5-=/@36[Z>06ZW-YX*T^X=(YXG7\$/^":W[?7BS_@GA^TKIGQ9T
MG1[KQ?X#U_39_"GQA^'MO>PVE_XF\#77V75'U+29KF.X73/$O@_7(V\3Z'<W
M(%EKMXUQX>FN-%TZ];4X6VVDNP'^GS6?J=W'86LU[<2>3:V=O=7=Q*REHHHK
M6WDN'EGV_O!%&D3L0GWF"J3D@'\ZO@W_`,%>/^"<_P`;O#&F^)O#G[5/PM\+
MF^LXKJ[\._%#Q%8_#/Q/HLTDBP-IFJ:9XOFTR)M3AN72W:#3+S4HIF;S;.XN
M;?$S?EA_P5H_X+H_L[^%O@1\0_@5^R/X\B^+7QJ^)F@ZEX"F\=^#C=?\(-\,
M-"\112:1XIUB/Q0]NL&N^,AHLUY;>%K#08[ZUTW5+FW\0:EJ5NNDPZ=JB`^Q
MYO\`@X!_X)?Z;<WFGW/QL\22365[>6<C1_"WQ]=)OL[FYM)"MY#I%Q!<Q2RV
M<TMG<12>7<6DEHT082Q/+^K'P=^+G@?X^?"WP!\9?AIJ-SJ_P_\`B;X:TGQE
MX0U:\L;O1[G4/#FMV4.H:;>&PO8H;RV$UM-'(;>YBBF3)1U#`@?Y5/P)^"GC
M;]HKXP?#'X`?#/3KW4O'/Q6\4:/X+T&WM;<3LCO87%YJVM7Z1(XTW2_#.C:#
MK?CC5;R7=;:=H7AC4[Z1TL["Z\C_`%6_@[\,=!^#OPD^%_PE\)I%%X;^&7@'
MPEX!T/RXQ"!I'A70;#1+5TB7*H\\5@DKJ<8,C`_,.0#U"BBB@`.>QQ[]:X?Q
M]X&\-^/_``Y=^&/$]DEYI5]<6UPRD`/;W-K*L\,\$F"T,I9/*,D>&V2R("`[
M5W%07`!4`X&20.,G[I/RCH6R!CKZCFHGI%NTI6L[1=I.S3WNK+N[[7!JZ:NU
M=-76Z]#\$/VGOC+'H?[6WCV"[NVFT>WB\+Z'=PF15ETFXLM$AE;5;1XG>ZMW
M1Y$:]E@@0RP>7%'<QR1N$]S\'?M"_$3PK'8/9>*QKNBW7V21(_$$<FL6IBO(
MPT<R;;I=1EL8QRT=M?Q.H*[Y"X8G[%^+7[(7P7^*=AXKBN?#4>A>*?%^H)K5
MWXYTE'7Q-'KEM;0VUOJ`N9'<7=I%%!;Q76ARR0:;=P>8B1I/+-*?Q5^(/@WX
MM?L>Z_\`\(OX^TF37O`&HW<JZ%XKTB"?^SKMYI&!?3)YR8=)U"2,I)J&@7\Q
M\I-IM9&C(E?_`#J\6>!/%#@3B;-?$'*<PQ%7!9OF4,RYLAQ%>-"E1A-)T\3"
MM*:=5IKFE&*IS2;7O)I?$8BMF^2XFKBZKE4P=6M)N5TY*$I7Y)KE3:LEJK)^
MONG]&O@[Q+_PDWAW1=:6]T34/[1LXYI+K0+N:\T::5E#,;"ZG2.:2,$[1'=0
M07/&3&"&`Z_>?09[CD'U_ECWSVK\#/A)^T'X@\&RGQ+\._$0U+3+Z2*35=(O
M!+>Z;>2/N,!O[5IEN[74!%O_`--BCDNG`*MO7(K])_AO^V5\-/&8MK'Q+>)X
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M*.-$):221OE1$4%LD@9`^E:<L9>[+6+W3_K_`(8)6Y7S.44DY-QMS6BN:ROW
MM9^5RN[.&QN0!MH50A9AG.6;YQ\I``4@#D$G=T'\D_\`P<%_$+X2_%K7OA+X
M6\.ZM'=_%/X.>(/BCX.\;^&[JQFL-7T+3?$>C_#WQ!:/=+>1DSZ=KLEAHVH^
M&[VWF^P7L,>HV\:-<^>Z_P!5/BOQCX<\&>&]5\9^)]<TS0?"VAZ<^K:QK^I7
M=M:Z;::?`HF^T/J,S+%'`%*G<S!Y"Y6V5W#+7\CG_!1CQEX(_;]T7XF_M(?!
M?P9K-IXW_9RUS3/AMXJT2*(ZAKWQ.^`WBB9[;P3\6+/2X8+>Z@OO#7C;4=?T
M!]'33=9EBT?Q5X2N#?K)*MO!X7&F09_CN!.),VRG*:F,P648:E5S.K2@W]6P
M]3$4J,)J3VJ>TG3]U<S2EK9N-_Z*^AKXC>%_#7TJ?"3)./\`BFCDF8\35LQP
MW#6$PV98/+\37Q^+RW$X.A1QD\72J1J8+%*M4H55"IAYJHXR55TX54_.O^#<
M[XH:CX!_;`^(7P@>X8:)\8?A3>:C+81M$T#>)?AIJRZIH]^YP'5[7P_K?BJT
M6.(A/+U!%V+&BBO[:0V<`$9(SWQCI_/I[?F?X;_^"4_P'_:G^#W[5_PV^/-Q
M^R1\?/$?@+3;+Q)X?OM0@\,6O@>;3X_%EHVF-X@0?$"[\.Q:QI%A%;Q>8+";
MS;ZWCDN[<":)8)?[?;:=W\HD,/,B$AW(4*YV!4!!D0L`Q$X,Q8.BF-#&68?-
M^&;QJX8HT<=1Q%*>'KNE2>)5IU:,Z-&M&::C&+BIU)PTO9QLWLE^K?M!*'#$
MOI`YAG/"F:Y9FV!S;ASA^IF%;+,;@L<J>=87#RR[,*.*J8/%XI1Q-)X2E&7M
M%1E.FX24))N;UJ\"_:3_`&9_A#^UG\'_`!A\#OCAX<'BKP#XRMU^TVPE^R:I
MH>KVB.VC>*?"NJHC7.@>*/#UX8=2T/6+3$MG?P+(R312W,,WO$1R#SGGV^G;
MUQG\:EK]!/XA:LVNQ_!;^U'_`,&X/[7GPI\07^H_LT>(]!_:4\`!7NM-L=1G
MTKX>?%C2;2*Y"Q:1JOAW5M5_X1?79K<@1Q^)_#FM6$6JRK)<_P#".>'!#':R
M_F)J/_!*?_@HGI5_!HE]^Q+\=!>G&5LO"<&L0QJ)G!!U#1K_`%/2(6D,N]KX
MW<"S81I1YA#U_J$>3$`!Y:X&T`$9QL+%<9SC:7;;CIGC'%.5%4``O@'(S(['
MCU+,21[$D>U`C_.,^#'_``0?_P""D_Q=U"QMM0^"ME\$M#O+E$O_`!+\:/%/
MA_1=/L(9@JB_N=)T"^\1>)=4V($46MGI%U?7!C%M(=-B2.Z;^PK_`()C?\$H
M?A#_`,$X?">N7VF:_=?%'XY^/--LK+QY\7=2T9="1M-TYEO8/"7@KPX]]JKZ
M#X7M]5)NV2:^O]4U@6NG_P!K7TUOIVFVEI^M)C4G)!)R2#N;()&TXYXR.,#`
MIOD0XVB-0`,`@;6`Z??&&SZG.3W-`$M?B+_P75_8Q_:#_;;_`&<?A/\`#S]G
M7PIIGB[Q1X8^-VE>+]<L=4\3:+X7BM_#L7A?Q)I,]U%>ZW<VUM+*EWJ5J@A1
MI'56:9D,4;D?MU3617&&&1AAU(X8%3R"",@D>OIS0!_#K_P3H_X(M_\`!0[]
MGK]N7]E[XU_%?X2^&-"^'OPW^(3Z]XPU6P^)_@C7KC3M.E\)^(M,6X@T_3=5
M>]O=UW>0Q-#;V[O"&21GE,@B7^XB)S)&KG;\V2-C;E*[CM(;OE<$^^:5HHVZ
MH,\C<!M;YN6PRX89QS@C/>G@8&/3CDDG\2>3]3S0!QOQ%TN_USX?>.=#TJ);
MC5-:\(>)-(TR!Y%ACGU'4]&O+&QADF?Y(8Y;J>)'FD(CB5C)(RHK$?YXD'_!
MOG_P5.CTB.R;X(^#/-72K.U\M?C%X`/[WRYXY(C))J4$JAHW!^TBS=;60YDM
MYU&T_P"C6RJZLC#*L"&'."#U!QU!'!'0C(/!J-K>!D\MHD*$.NS:`N)`RR``
M8`WJS!L<D,0>":`/)OV??#6K^"_@3\&?!GB&".U\0>#OA3\.O">OVL,Z7,5K
MK?ASP;HFCZO:QW$7[JX2WU"SN(5FB+1RJ@D1BK"NL\;>`?"OQ$\*>+O`WC72
MK?Q%X-\=^'-=\(^,?#6I1I<:3XB\+^)M*N=#\0:#J=JZ[;G3-6T:]O\`3[JU
M8^6T5]=2J%N)?-'9!0N<9Y)/))Y/IDG`]`,`#@`"EH`_@$_:`_X-WOVZ?#?Q
MJ^(&B?`#P3H7Q(^"UMXBD?X7^,==^)/A3P_KEYX*U(G4=-TO6],U[4HM0M]8
M\(&>XT74IS'Y6NP6EA<6EO8NMPTO[D_\$"O^"?W[4O["[_M1+^TKX(TCP<?B
M8OP?E\'?V1XM\/\`BI+^/PHGQ$AUIKF31+ZY-A+$^MZ<T5K<1AQ%+N:9RP`_
MHM\B+!&P88;6P6!8<XW$'+$9)4L25)RI!YI4BC1F9%VEV9FP3AF;8&8C."Q"
M+\V,\<'DY;;>X$E?RI_\%U_^"9/[8W[;?[4?PI^)?[.GP\T'Q=X/\,?`;3O`
M>M:EJ_C[PQX1FMO$]I\1O'VNM8P:=K]Q;3WT?]GZW82_:(98XV:1D0L4-?U6
M5'Y,6\OY:[RV\MCYMVQ$W`]0=D:+QCA12`_EE_X(1_\`!,S]L;]B']HOXO?$
M#]HWX?>'_"7A;QC\&[;P=H=_I'CGP]XJFN=>@\9:9K36LEEHEQ=/:1"RM[AU
MO)9WBE9!&(XF*EOZGJC\J/?YFQ?,_OX^<X7;@MU(QQ@DC\:DH`_G"_X+Z?\`
M!/[]J7]N;4?V83^S?X'TGQA'\-;;XI#Q?)JOC#PYX6%@?%TO@:#1TMUUR^MI
M+Z2Y71M2.((RD/DJ\DC`&(_%_P#P1H_X)._MQ_LA?MQ>&/C=\>?AEX?\+_#[
M3/AE\3/#M]JNE?$/PGXIG36?$MCX=M-*ACT_1;VXNWA)LKH3OL#!D#*%4,K?
MV%,BMG.[E2AP[K\ISG[K#!YX888<8(P*0Q1D*"H(5@R@Y(##)!`.1D$G'IVQ
M@4`25\C?M\?"WQI\</V*?VJ?@U\.=-AU?Q_\4?@)\4?`W@W3+F\@TZUOO$GB
M+PCJFG:1;7-_=,EM:02WL\*22S.B@-@,I.X?7--9$?;O56VL'7(!VLIRK#/0
M@]#0!_G2'_@@#_P5%$B+_P`*2\'A5D1R/^%Q?#UI"R3Q7!0JNJ`H)'MY/(9U
M#2*1$560>8W]#G_!:'_@G]^U/^V5^S_^Q;X%_9_\$:1XI\2?!_\`M"3Q]::E
MXM\-^'HM'\[X>:#H>(;O5M4M[7491J5A+"(+.=RRCS$E<,M?T?&-"2<$$J5)
M#,"5(Q@X(Z#[O]TDLN&))3RH^,KNQ@@.6<`J,`@,2`0.X&>ISF@#_.I_XA^?
M^"I^[</@EX/7Y`N%^-'@`8(.2X8:J&5F_BVE0<D``$BG?\0_G_!5'_HBOA/_
M`,/9X#_^6]?Z*OEI_=%'EI_=%`'^=5_Q#^?\%4?^B*^$_P#P]G@/_P"6]?L5
M_P`$1/\`@EW^VM^Q=^UKXK^*O[1?P_T/PIX'U'X'>*O!6GZG9_$'PKXGEN/$
MFJ^+?"6I6-C_`&=H]_>W4%M!8:3>*=0N%*7,DF?)3>JU_67Y:?W12"*,,'"`
M./XAD,0-V%9LY91O;:C$JN>`,#``LC;48XST&.>Y`Y(!(`SDG!P,D\"OY+O^
M"X?_``2X_;5_;8_;+\'?%O\`9U^'/AWQAX$T3]FGX??#G4-5U/X@^%?"T\7B
MG0?B7\:?$FHV$>FZU>0W5Q##I?C/1)A?ILADDGDA2(F-GK^M)E5U9'`96!5E
M/(*D8(/J"."*8(8PS-@DL<G<[L/NHN`&8A1B-?E4!=VYL;G<L`?S#?\`!!S_
M`()O?M=?L-_&']H?Q3^TEX!T'P;H_C[X:>"-`\*W.E^._#7BMM0U;1O%>K:E
M?6T\&AW,\M@L=M=0NDTY=)R[*@1H<2_T]J?D!`/"\`YSP..H!Y_W<^U-,$1;
M>5.=NP_,X5EY^5D#;&')QN4X!('!-2`!0%4`!0``.@`&`![`<4`?S_\`_!>G
M]AG]I/\`;D^&G[.7AG]FSP=H_C+6_`/Q(\9Z_P"*+75O%^A>$X]/TC5?"5OI
MEA<1W&N3017LTUS$4-I"4DC4O,S[8@DWY4?\$K/^"._[??[+?_!0G]FOX^?&
MKX6>%_#7PQ^'FH?%FX\4:[8?$SP?XAN[`>)_V?OBYX#T3R]%TF]FOKU;GQ'X
MLT>TE:$I]F28S/F,,4_M2%O$"I"XV`A5#.$7(()$8;9DAF&=N>3SS2M!&Q4E
M2"I!!5W0C#I)U1E)!:--RG(9048%&92`8.O>&M"\8Z!K7ACQ1I=CKOASQ'I&
MI^'O$6@ZI:P:AI&N:)K5E<6&KZ5J-E=PR07>GZC87MWI][;R(T5S:7$]O*&2
M1UK^/S]NS_@VH\50>)O$'C_]@[QEX?OO"^LS3:@?V>?B9JUSH>KZ!<R*B30?
M#OXCSB_TW7M(9GD-MX5\:0>'9=-M;>/;XUU&<I&W]DB(J#:BA1N9L#IN=B[G
MZL[,Q/<DFF&"$EB8U)<$.2,F0'/RR9^^@R0J/E5'"@``4`?YC'C+_@DQ_P`%
M)_!^I7%GK?[&/QFU*9':$WWAO3--\:6=RJPE#<Q:KX:U?59KJ)HRT*"\17"$
MVTC_`&9I(SZ_\$O^"&/_``4E^+WB#3=.F_9_E^#>AM/:PW7BSXR:UH?A#3K&
MTG(W746DZ;+J_BJY2(S;ETFWTIKEY5<PP_.\L'^D6$4=`>H.-S8!``&!G"C`
MQ@`#VY-,,,;`JR[P0P(<LX8/]Y6#DAE/96RH[`4`?C[_`,$MO^"0OP;_`."=
MGAR^\52:\WQ=_:.\4Z3-HGBOXQW_`(=7PY:Z/I$]Q!=WGA/X:>&;G4==O/"W
MAJXO;2RN=4N-0UO5M;\27VGVM[J%S9V<%AHFF_L,HVJ%R6P`-S'+''&6/<^I
M[GFD5%0848&<XR2!P!@`D[0`!A1@#L.33J`"BBB@`HHHH`*Y/Q7X5\/^--%U
M3PUXJT73=>T'5X#::EI&K6D%_INH6S=8[JVF4HZ$@91PRG'J,UUE0O$6)((`
M//?/3N<^O..G2L,1AZ.*I2P^(H4L10JKDJ4ZJ3ARO1Z--/32VUKD3CSQE!VY
M9)QDFKW3T?E\FK,_$?XX_P#!+SQ%X<U"]\>_LL>+SHEP`TES\./%5P3:7"[A
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M_"]_'?Q65NP`1WFTJWE/E,/[2,2HD/U%H?\`P4<^,VBB"#7M+\#>,(]V7>9+
MK0[VXC``98'T6?5[&5R1@M):N`P(`!&![C\8/^"/7[,?Q"WW?@J?Q9\']5\Y
MKR`>%]237/#\-T5`0MX?\317JI;HP#+%I=]I$B*%CAF@55Q\+^,_^"/O[67A
M@N?AO^TUX2\;6"[IDC\5Q^*?!6H))PJQQ:;=W?Q*TJ>.-"%!GU^PR%!6-0RQ
M1_F</##QMX+J2H\-Y[C\=A5)*,,)FZHT(Q7*_<PM:SA'76*BTW=K1I+XC$Y1
MXA97=9=5A5A"5HT\-*G[&,59KDIU9QDT[MMN"]Z_<^J;C_@JCJT4823X%Z7<
M7B[50Q_%6>WB>5F58T9Y?AG<,H9V7+&*15#?.57<R='\9?VPO$?B[]BSQA\1
M+SPA:^`&^)>LW_PS\!V%OXC?6[S6M%NH6M=?UF.]DTSP^MM+-IL6O0:;!#:P
MO;E(KU)]P4+^5&K_`/!._P#X*=6#/#!HOAC4K9$.9[3QSX1;ST;Y98%BN+JQ
MG:29-T,9RN'D5LMC:??OAU\$?^"H]UX.\-_##XQ_LW?`CXU_#/P]`;;1?#_Q
M#\?Z!X(\6^&[9A)$\VB>._`UZ=9T74+J%]KW$NCZS&8HR3;7$@C=/VCP8XFX
MZRSC;+L;XI4,XQV0X9T9+`X'!4:F%<H24G#$QYJ<YQ=DW=N_*KMQO;Y/BC_B
M+'$7"G%7#F&JRRW,LZR?%99D6*Q.'J0IY;BL;&.'EB,14PD?K*C"A.OR3I-S
MA4<9*T.9GY_?$;XJ^(M4\$^%_!OQ`^(GB'6?!7@:PMM'\)^&;V\:72[&WTZ'
MR=/2VT9G,<ER@46T<&JWM[>6EI%;!+YK46UM#^?VF?&G]H;P1\8](\3_`+-6
MO>+O`OQ)U>*Y\!>$['P2D6H^)-7'C*ZTJS_L:VT^ZTG5;;4=5U>YL+%=.+Z%
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M_`?X0:CXA_:M^,WQ$^,'[0GQ=UFR\5>/&\9^--:\5:)\/]+L+2XM?#?P\\(V
M5WK%YH>D)I<%W=7WB&]\/V=K::UK5_-"XN+'1=#EB_32J:13*RD[-HD)XR3M
MP0>>[YQGMU^E7*_A_'XZKF6-Q./K4:.&JXNM.M/#8:,88;#N3THX>,4N6C"-
MHP3N[+5N5V_]=,ERRCD^5X++:%6O7IX6C&E[?%RY\77DF^>OB9[2JUI7J2:2
M^+9;(K\%?^"YE[X+L+?_`()ZI\4]0\7Z?\']4_;AT&P^+T'@B\\9VNK:QX`?
MX5?$>75["Y'@&ZLO%%[9-'$#-9:>;F1E562"=XTC;]ZJ_*7_`(*:?!']HGXH
MZO\`L3_$;]G+X8>&OB]XI_9B_:VTCXZZYX&\5_$S2?A#I^MZ+I7P[\<^'+:Q
MM/&NM:#XK2QN9]4\0Z<)#8>'M5E$!N7^RJP*CD/3/R4^'7C_`/8[T#_@H)^P
MYX,_X)R_%SXT>#/%GC#XC>)S^T/X+^+/C[XP^&_ACXU^!NF^"=1^V:+;^$OC
MMJ4#>+/B1<>)E\/#P'IWA2VO]92*36M0N'^S6KD_U;63*0-K,VZ)'.Y&B*JW
MRQ#RV4%'$:"*9&(=)(<,BDY/X??$[X5_\%!/V[OB9^R[H/QU_9@^#G[)/PK^
M`'[2?PO_`&F/$_CG1/VIK;]H?X@:_>?";5++Q#X=\"^"M*T7X/?#I?"W_"4:
MMIXL_$6HZI>7.G7/AV[N;N)HM3M(-+O/W'@B>-G9]F7);Y"QP6P-I+*"=J(F
M9,@RNS,R*0"P!9H/(/THH)P"?3F@#\G/^"AFJZMIO[2'_!):WL=3OK"+5?VZ
M-1TO5K:SO+VTAU2P_P"&=/C-=FQOK>"3RM0LQ-9P7BQ7Y>..6W@G1?M$<97]
M78=@#*JD;6(!.,M\J,3],L!^`K\]OVR/@5\2/C1\;?\`@GGXX\!:9IM]H'[/
MG[5VH?%?XG/J.MZ?I-[IO@Z7X&?$_P`&Q7&EV5[+'+K.I-X@\5:-;-I5KBZB
M@FFNY52"VD:OT'B8%B000V]E((8,H\I2P(SW&,'!H`L4AY!'J#2T4`?CO_P4
M8\4_$;XC?'3]B+]@GX??$/Q9\(M#_:L\2?%7QE\;/B-X%UF_\/>/X/@?\`](
M\.:WXK\!^"O$6ES1:OX;UCXG:]XL\/\`ANY\36>IV4FBZ7*\\']H3,=/N_FC
M]M3]ACX:_P#!//\`9_\`$G[;'[!TWB[X(?%/]FN/0?'GBWP_;?$'QIKOPX^/
MGPRTW7;.W\:^`/B]X;\4^(]0T'4+:XT*_O[^+Q*L*:EH,UI>7EG)!=7GVN#[
M]_;U_94^+?Q:UC]GC]H[]FOQ#X6TC]IO]D/QOKOB_P"'.D>.FGLO!GQ1\(>.
MM'7PS\4/@]XCURUAO;CPK!X[T)++^S?$J:7K,.E>(]&T.ZETZ*%'N[;Y!^.?
MA3_@HA_P44\+:3^S)\4?V6_"O[$OP"\3>+?!=Q^T5\2K_P#:(\._&;QWXR\#
M>%O$&F^)]:^&'PD\.>%_!VAK;)XJU#2].T[_`(3;Q%>FQCM9[@W7AN>&&6RU
M$`_;3P)XD@\8^#?"WB^UMY;2T\6>'=#\3VEI.PDGM+77])L]6@MIYE>1+B>"
M*\6*:=&V2RJ[(JIA1UE8OA[3-.T;2;+2=(LK;3=+TRVM-,T[3K,H;;3[#3;.
MWT^QL(0BJ$2SM+:"W6+YS$(_+\QP@8[5`!7X\_\`!<+5M9T7]C#PU>:%JNIZ
M/?/^U+^S%9M=:1?7^FW<EI>?%/2;>]LS=Z=<6T\<%Y;2203K)(;:2-V2Y1HF
M85^PU?F9_P`%9?V>?B_^TS^RC;?#WX'^&=$\8>.](^-/P;^(\'AWQ#XHTSP7
MIFI:5\//&-KXDU.WD\3:O;W=CI,LD=I'''=-:W<T6]I8+.\DC%M*`?I1!)$I
MG'FHQ-Q+\JD$Y4*'0(LDF60JP<(D9WAC)'YOF2/:!##*D,#T(((/;J..O%?F
MA\-/V@O^"D7B/XC>$O#_`,5/^"=7PL^%WP\UG6_LGC#Q_HG[?_A_XCZSX/T1
MDBEN=:TWX?V_[.?AJ[\6WNG#$O\`84'B#3.92(KUXY%4?I5;[O)CW;MVT9WY
MW'_:;*1D%AR044C.,#%`$U5+LX5"0"FXAC@%ES@%USQA(C*TG()C#`9)`-NH
M9HS(``1QN&T_=.\;220"<JI8KCJ3@D`DT`?AO\?_``[JG[?7_!1SQA^QGXV\
M9^.-`_96_98_9^\!_$WXH?#'P)XHUGP5=_'KXN?&#5=:?P_H7CC7=!NK.\G^
M&/A+P9I]C.GAZ2>*PU[7M2U*SU=Y=/B\JN2^)GP1\._\$N?VD/V-OB)^RUJ/
MBCPQ\!/VDOVB_!'[)WQX_9OU3QOXGU_X;W&J?&2YO=)^'GQ<\!Z1XNUG7)_"
MGB[PQXQMK?\`X2`Z5YJ^(=$>+3KV:R*Q74WTK^TW^SS^TQ\,?VN]'_;U_8[\
M+>#/BOXF\0?"?3/@5^T7^SAXN\8+\-D^*G@?P[XGU+Q!X'\=^!/B->:3KVE^
M'OB1X*.L7]I=:?K.CMIWB;1X-+TN*]M9;0SMYWIOP@_;"_;=_:3^`7Q2_:H^
M"_A+]D_]GC]E'QLGQH\&_!>T^*MC\8?BC\:?CE8V=WIW@KQGXQUKPQH_A;P]
MX"\#_#6-XK_3/#QM_$>J:OK>GP2M?2:7<)#9@'[54444`%?CI_P4$UGQQ\;_
M`-I_]DC_`()X>"_'WBOX5^!_C_I_Q9^,G[27C'X?:K<>'O'NJ?!;X.0:%$/A
MIX2\2V36E_X:E^)'C;7=,TK7]4TF_BOXO#-IXDG>.8.MAK7[%U^9G[>7[-'Q
MF\?^/?V>/VK?V6]0\(I^TG^R?X@\77&A>"_B!J<VC^!_C)\,/B-HL.B?$GX0
M^(O$4%EJ3^#;CQ-9Z?877AOQ5+IFHV^C:O;07SPN,QD`_,'XI_#W_@G)^Q_\
M>OAW8_LE?MD?#7]C[]IGX5?%+P3IOQI^#_C/XN_$OQ-X0^,_P[U1+.Z\4?"[
MXF^"=1O/$46L^(_$7AZ87/AOQ%96D6HZ-=S37ZOLM&:#^F2VC,<TV!B,Y*AL
M^8&9MTI9BTC2[BRGS#(,;0@0!<G^>']LSP1_P4[_`&^_@IJGPCM_V//A1^RK
MX>L?&WPR\;>-+SQG^T-X/^)?C+XRR^!OB3X1\1#P'X*?PYX'\-:7X6T73]0M
MYO%;>-?$\\]QXH7P]IN@V&EZ9<ZQ/,/Z(+>4222,OS*X#(X&Y2F$*[9,CY61
MDE"A2N),AV(8``MTC9VMCK@X[<XXY.0.?8TM%`'Y)_\`!7O4M4TGX!?`.?3-
M2U+29[G]NW]D33YY=.O+G3[E[&^^*5O;7=I+<Z>\<LMG<AY%ECRJ2Q-LG5H]
MRG]98EP\I`P-Q`'``.225"X'S$[F+?.6)R<8`_//_@HW\"/B3^T;\)?A'X2^
M%NF:;J&M>$OVK?V;_BMK4>M:WI_A^VB\'?#OX@+XA\67%O=:A(D=SJ5AI<#S
M0Z5'_I=XY2.!6+9'Z%PS*[.H#9!WD$`%0P79O7.Z-G7YE1U5]O)`H`L4AQ@Y
MZ8.?I2T4`?E%_P`%3OBQ\3O"WP^^`?[/_P`%O%VI?#/XC_MI?M-?#O\`9Q/Q
M4T$M!XB^&O@#6Y[W5?B'XI\*7CPS_9O%B>&+2?2M*N1&EQ82ZUJFI6%Y9ZC8
M6=U#Y/X[_P""//PN\'^%+#Q5^Q+XX\>_L[_M;>#=3\/Z]X*^/.O_`!3^*7B[
M_A.[VSU2TU/Q!H7QWTC4/%6H+\2]#\9:-'K]GK,-SID;V]W=6\R6^H66D7.G
M7OUK_P`%#OV3?&_[4GP>\*-\(/%>@>"?V@O@+\8/A_\`M%_L^^)O%-M=W?A2
MV^)?PUOS>6OAWQ9'8HUXGA3Q9927VD:K>6]O=R6$E[#J4FG:C;V,FGW?QA\7
MK_\`X*H?MD_#JZ_9?U3]E_PI^Q1IOQ$O=`T/XT?M1:1^U)9_$:YT#P-IVN6-
M]XPD^!?@_P`%^&?"7BZ_\1>.-!L9M(TF[U#Q/H'_``C,&I265U=22+!X@@`/
MVU\/#4UTBR36S8G64MK4:N-,:=M-74VM('OUTXW21W9L!=M*;+[2D<PMC$&A
MMP!;0[58/A?1H/#GA[1O#]K/=W-MH>FV.CVT^H7+7FH2VNEVL-A:O?7CL\UY
M>/;6\+7%U<R2W,\I:6>1Y&8G>H`*_-3_`(*U:9^T=K'[%'CO3_V9++XAZEXM
MG\3^`/\`A.M/^#MY+IWQGO\`X,Q>*;";XHZ?\);^`/=6OC34?#L<FGI)86U[
MJK:!=:]%H]E<ZK)9QG]*Z^,/VZ/A?^T?\3/A%H%Q^R?\3K'X<?&[X:?$_P`#
M?%?PYI_B&_OM.\"_%?3O!FH27&N?!_XB7FFPW=[:>$O&-C=&26[AT^]2#6=*
MT9;V./39;Z9`#\,_@%#_`,$V]5_:,_9NC_8#_:"\5?L;_M1>'_B9IQ^)WP*_
M:"D^-GA7Q5^T5\,8K'68/'_PP\<_#_XIZO#;^)O'6IWMQ%-X?UK[3<SZ1J#S
M:IH]A>WZZ;<1_P!3$6WRX]A)78NTD@G&!CE?EZ?W?E'1>,5^`_[17P]_;V_X
M*-:-\*O@;\6?V*?AW^R=X>\*?&_X6_%GQ9\?_$'[2?A?XUZEX2;X8>*;?Q7)
M9_`[PKX6\`^'=9UC7O%VG:?;Z9'K\VM>%K'24O+RQOH)R7U2']^(V+HK%64L
M-VUL!ESSM8`D9'0X)&10`^BBB@`HHHH`*@;[[=>".Y_NKVZ444`9DDKIPN`2
M!ABS=2$]P/XNG?IWK)O]5>V5L+<.8P&81JSEAT(50"3G<".O..N:**`/+O$?
MQ:7P^)'?PIXXU-8RP(TG0KB[)VJ#@%%(+$D''7:5^7+"O'3^UWIPO/L(^%/Q
MS5]S#[4G@"]6QB]I)9)@ER3U\S8F0"I48HHK2,(M7:3;_P"&,9?$_E^2/8?#
M?Q6MO$(6:W\,^,=*PH<G4O#OV,@\D9*7.Y5'(.U"6'RMPQKU&PNS<6T3A)8@
M<!1*IB&>.?LHQ&IY.<J5)YV@BBBE-)W4DI*R=G&-M[6T2T_K96%AJ]6NOWK4
MK)Z<D$M-5>T4]++J;$8PHP2H8C>J8$9&!E=@`7!))^4!AV/``L"-7*N2P(<L
MF&8;&,>W*X(XQG@Y!)+=:**QC!1=XW2M\-_=Z:V[Z!*7/#F:BI*JHII6?+9N
MS^9H#I^+?S-+115FT=EZ+\@JL;6/S&E'RNQ4EE5`Q"LTBHS!<L@D9I-I)RQY
M)&`"B@8]8$1@XY<`@,P#,%)RR!SE@A;D(#M4_=`'%3444`%!Z'M110!36RB1
M0@+E1N(#-GYF"@G_`&AD;RC[XRYSMX7%A(PA8YRS;03P/NC`P!A1ZG``)[44
M4`24444`-90RE3D!@0<$@X/!`8$%21D94@CJ""`:K+9QHS,C.A92I"L0I!P&
M)3.TNP4!I6#2G'+T44`310K"&52VUFW!3@)&-B)LB50`D?R[MH'WV<Y^:I:*
M*`"HY(A)C)*D9P5P&&<9P>V<8(_B&0>":**`(1:(%9`\FUF+E2VX%F=Y'+;]
MVX,[EBA^3@*%"`*+"JJ*JJ`JJ``%`4`#T4``#V`Q110`ZBBB@""6W65@Y9E9
M=FTH<8*,6^8#B3J0HD#",DM&%<EJ8;5-JKOD^5BX8MN8.0=S`L#ALDE2H&S)
M"!02***`+5%%%`!4#6Z.=V74_/\`<=XQA_O95&4,WH[`N.Q&3DHH`3[.-NT2
M2JISPKD'!#`@'J!\Q(_B#88-D4D-LD#R2*69I`B9;DB.-I'1,_>;:\TS[G+.
M3(06*A0I10!9I",@CU!'(R.?4=_I110!66T1"[(SH9&5W*;4+NJA`SLJ@N%1
M4158E52-44!<@R10K",!F;`P"YW,`3DKO.6*D\X)(';`P`44`34444`-90RE
M3W[]P0<@C/0@@$'J"`1@BH!:H`<O(2V-Q#LA9AC:Q*%<D;0.<D@;6)7`!10!
M,B!`0"3DYP>@^4#"@`!5XW8'&XL>]/HHH`*BEB\T*-[I@@G:<;L$'!QSVQD$
M$`G!HHH`B-JA`^>7<"Q+"0AFW*Z[9,?ZQ0'.T2;MI"E2",U/&@C1$!)"*%!/
14@#&3ZGU/K110`^BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
